Physician profile
Melanie S Splitgerber
NPI 1861692832
$2,474.68
in general payments reported to CMS, 2019-2025
30 companies · $592 in 2025
The $592 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.82 · 2024: $1,865 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $469.58 | 2024-2025 | Korlym |
| Abbvie INC. | $309.95 | 2021-2025 | |
| Axsome Therapeutics, INC. | $253.60 | 2024 | Auvelity, Sunosi |
| Novo Nordisk INC | $201.85 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $175.73 | 2024-2025 | Repatha, Repatha |
| Supernus Pharmaceuticals, INC. | $153.75 | 2024 | Qelbree |
| Lilly USA, LLC | $86.29 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $83.97 | 2024-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $74.20 | 2024-2025 | Airsupra |
| Lundbeck LLC | $57.14 | 2024 | Vyepti |
| Astellas Pharma US INC | $52.71 | 2024-2025 | Veozah |
| Ironwood Pharmaceuticals, INC | $51.90 | 2024 | |
| Aimmune Therapeutics, INC. | $46.49 | 2025 | Zenpep |
| Antares Pharma, INC. | $45.03 | 2024-2025 | Xyosted |
| Ardelyx, INC. | $37.73 | 2024 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $37.69 | 2024 | |
| Exeltis, USA INC. | $37.65 | 2024 | Slynd |
| Bausch Health US, LLC | $37.04 | 2024-2025 | Wellbutrin, Aplenzin |
| Exact Sciences Corporation | $33.94 | 2024 | Cologuard Collection Kit |
| Averitas Pharma INC. | $31.59 | 2024 | Qutenza |
| Esperion Therapeutics, INC. | $31.37 | 2024 | Nexletol |
| Recordati_rare_diseases_inc. | $29.96 | 2025 | Isturisa |
| Insulet Corporation | $23.03 | 2024 | Omnipod |
| Pfizer INC. | $22.81 | 2025 | |
| Tris Pharma INC | $17.26 | 2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $15.47 | 2024 | Benlysta |
| Ibsa Pharma INC. | $15.01 | 2024 | Licart, Tirosint |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.52 | 2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $13.80 | 2024 | Quviviq |
| Philips North America LLC | $13.62 | 2025 | Patient Interface Software |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Splitgerber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.